• Startups Taking Multi-Cancer Early Detection Testing to the Next Level

    Jul 10 | Diagnostics World | A growing number of promising young companies are developing tests that are particularly good at picking up early cancer, initially for a single type of cancer but with the potential to eventually be extended to multiple cancer types. A handful of these startups will be spotlighted at the upcoming Next Generation Dx Summit . More

  • Fragmentation Approach to Finding Remnants of Cancer in the Blood

    Jul 09 | Diagnostics World | Molecular testing for minimal residual disease (MRD) is increasingly being used to detect cancer recurrence, and to that end many companies are actively developing assays. The tumor-informed approach based on the genetic mutations of patients has been particularly popular and often employs cell-free DNA (cfDNA) and more specifically circulating tumor DNA (ctDNA) analysis. More

  • Blood Test Detects Cancer with 95% Accuracy Using Microbiome RNA

    Jul 08 | Diagnostics World | Researchers at the University of Chicago have published a new approach to cancer detection offering early unprecedented accuracy in identifying both early and late-stage cancers through a simple blood plasma test. The results were published today in a Brief Communication in Nature Biotechnology More

  • Digital Pathology’s Flywheel Effect: Growing Momentum, Growing Opportunity

    Jul 03 | Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns. More

  • Digital Microfluidics Expanding the Value of Syndromic Testing

    Jul 01 | Diagnostics World | For patients who suffer negative health consequences from a delayed diagnosis, new-to-the-scene digital microfluidics (DMF) technology for multifunctional testing can literally save lives. A standout in the field is Baebies (Durham, North Carolina), which has developed a pair of such platforms cleared by the U.S. Food and Drug Administration (FDA) intended for rapid point-of-care testing to aid diagnostic testing in newborns. More

  • Galatea Bio, Fabric Genomics Combine Pathogenic Variant Analysis with Polygenic Risk Score

    Jun 26 | Diagnostics World | Galatea Bio and Fabric Genomics announced a strategic collaboration this week to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. More

  • Follow the Money: Neuroplastogens Novel Therapies, Genetic Medicines, More

    Jun 25 | Diagnostics World | Elkedonia SAS plans to develop the drug-like small molecule inhibitors of Elk1, a novel intracellular target that plays a pivotal role in reward brain circuits and neuroplasticity; SpliceBio will advance the clinical development of their lead gene therapy candidate, SB-007, for Stargardt disease; and more. More

  • Veeva, Sarah Cannon Research Institute Collaboration, City of Hope Receives Grant, More

    Jun 24 | Diagnostics World | Veeva and Sarah Cannon Research Institute has entered a strategic collaboration; City of Hope was awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health within the US Department of Health and Human Services; and more. More

  • Nanoneedle Technology Could Transform Medical Diagnostics

    Jun 20 | Diagnostics World | Researchers at King's College London have developed a diagnostic tool that could enable doctors to sample tissue during critical medical procedures. The nanoneedle patch technology enables physicians to extract molecular information from living tissue without causing damage or killing cells—a capability that could prove especially valuable in delicate surgical situations. More

  • Real-time Molecule Monitoring Could Put an End to ‘Reactive Medicine’

    Jun 17 | Diagnostics World | Modern jet engines can generate a terabyte or more of data per hour that gets transmitted back to the engine manufacturer to ensure aircraft safety and prevent disasters from happening. Yet the human body, arguably the most important machinery of them all, gets checked only once a year or whenever something has already gone wrong. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more